Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin
Response to Bowker et al.
- Azeez Farooki, MD and
- Stephen H. Schneider, MD
- From the Memorial Sloan Kettering Cancer Center, New York, New York; and the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, New Jersey
- Address correspondence to Azeez Farooki, MD, Memorial Sloan Kettering Cancer Center, 1275 York Ave., Box 296, New York, NY 10021. E-mail: farookia{at}mskcc.org
Response to Bowker et al.
We read with interest the article by Bowker et al. (1), which suggests that sulfonylurea or insulin therapy may increase cancer-related mortality. The premise that insulin is mitogenic for neoplastic cells is not proven. An expanding body of epidemiologic literature has linked insulin resistance and IGF-I, rather than absolute levels of insulin, with cancer incidence and prognosis.
There are several …
In this Issue
August 2006, 29(8)
Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin
